Story perspectives

Vertex to Acquire Crinetics for $10B at 102% Premium

7/8/2026

Summary

Vertex Acquires Crinetics

Vertex agreed to buy Crinetics for $85 per share, a 102% premium valuing the deal at $10 billion and a price of $8.8 billion.
Vertex will fund the deal with cash and a $4.5 billion bridge loan from Bank of America and Morgan Stanley, targeting Q3 2026 closing pending approvals.
Vertex expects Palsonify and atumelnant to generate $5 billion in sales by 2029, while Crinetics shares doubled and Vertex shares fell about 2% after hours.

Summary

Vertex Advances CAH

Phase 2 data showed atumelnant lowered glucocorticoid doses and normalized androgen levels in CAH patients, a result Vertex called “the holy grail.”
CAH has only one FDA-approved therapy, Neurocrine Biosciences’ Crenessity.
Vertex is adding pain, heme and renal pillars after its 2024 $4.9 billion Alpine Immune Sciences acquisition.
Vertex reported $11.9 billion 2025 revenue, mostly from cystic fibrosis, and said its newly approved product Palsonify generated $10.3 million in Q1 sales.

History

Historical Context

In 1999 Pfizer completed a $111.8 billion hostile acquisition of Warner-Lambert, creating the world’s largest drug company and igniting a wave of mega-mergers. The pattern resurfaced in 2024 when Vertex paid $10 billion for Crinetics, financed by an $8.8 billion loan from Bank of America. Analysts say such deals echo the late-1990s consolidation that prompted tighter FDA merger scrutiny.

1 of 3

Vertex Acquires Crinetics

Vertex agreed to buy Crinetics for $85 per share, a 102% premium valuing the deal at $10 billion and a price of $8.8 billion.
Vertex will fund the deal with cash and a $4.5 billion bridge loan from Bank of America and Morgan Stanley, targeting Q3 2026 closing pending approvals.
Vertex expects Palsonify and atumelnant to generate $5 billion in sales by 2029, while Crinetics shares doubled and Vertex shares fell about 2% after hours.

1 / 3